Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivaroxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivaroxaban SCHEMBL77766 | 1.00 | F10 (1.00) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL7721848 | 1.00 | F10 (1.00) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796329 | 0.99 | F10 (0.98) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796410 | 0.95 | F10 (0.90) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL30893049 | 0.94 | F10 (0.90) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL3375861 | 0.93 | F10 (0.86) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL13068882 | 0.92 | F10 (0.85) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL5478295 | 0.92 | F10 (0.85) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL12396723 | 0.91 | F10 (0.83) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL20802158 | 0.91 | F10 (0.83) | F10F2ABCB11ST14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14702 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122084795-A | Detection method of rivaroxaban tablet related substances and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137694-A1 | NOVEL RIVAROXABAN FORMULATION | Shanghai Auson Pharmaceuticals Co., Ltd. (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| CN-119185220-B | Rivaroxaban tablet and preparation method thereof | 北京悦康科创医药科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026098615-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUGS FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES | 上海东西智荟生物医药有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4739305-A1 | BUDIODARONE FOR CARDIOVERSION | Xyra, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-1685841-A1 | Prevention and treatment of thromboembolic disorders | Bayer Health Care Aktiengesellschaft (DE) | 2006-08-02 | — | — | EP | claimed |
| WO-2006072367-A1 | SOLID, ORALLY APPLICABLE PHARMACEUTICAL ADMINISTRATION FORMS CONTAINING RIVAROXABAN HAVING MODIFIED RELEASE | BAYER HEALTHCARE AG (DE) | 2006-07-13 | — | — | WO | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| JP-2006513227-A | — | — | 2006-04-20 | — | — | JP | claimed |
| EP-1583761-A1 | METHOD FOR PRODUCING 5-CHLORO- i N /i -({5 i S /i )-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&rc ub;-METHYL)-2-THIOPHENE CARBOXAMIDE | Bayer HealthCare AG (DE) | 2005-10-12 | — | — | EP | claimed |
| US-20050182055-A1 | 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide formed by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one hydrochloride with 5-chlorothiophene-2-carbonyl chloride | BAYER HEALTHCARE AG (DE) | 2005-08-18 | — | — | US | claimed |
| WO-2005068456-A1 | PRODUCTION METHOD | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | claimed |
| US-20050064006-A1 | Stents | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | claimed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004060887-A1 | METHOD FOR PRODUCING 5-CHLORO-N-({5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2004-07-22 | — | — | WO | claimed |